GlassScriptPhysician profile
Ivan Maya
NPI 1730111527
$6,859.27
in general payments reported to CMS, 2019-2025
36 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $225 · 2021: $375 · 2022: $975 · 2023: $1,603 · 2024: $1,469 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,132.42 |
| Education | $205.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $916.05 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $836.05 | 2019-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $780.59 | 2020-2025 | Acthar |
| Amgen INC. | $727.24 | 2019-2025 | Tavneos, Krystexxa |
| Baxter Healthcare | $382.50 | 2019-2024 | Renal - Pd |
| Calliditas Therapeutics US INC. | $377.67 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $311.42 | 2019-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $271.59 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $263.35 | 2019 | |
| Horizon Therapeutics Plc | $244.13 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $197.92 | 2022-2025 | Lupkynis |
| W. L. Gore & Associates, INC. | $187.76 | 2019-2023 | Balloon Wire, Viabahn Endoprosthesis With Propaten Bioactive Surface |
| Astrazeneca Pharmaceuticals LP | $183.95 | 2019-2023 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $168.44 | 2019-2025 | Veltassa |
| Cordis US Corp. | $164.40 | 2023-2025 | S.M.A.R.T., Opta, S.M.A.R.T. Control |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $141.98 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $62.65 | 2019-2023 | Ultomiris |
| Glaxosmithkline, LLC. | $61.46 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $60.40 | 2021-2022 | |
| Corcept Therapeutics | $58.49 | 2025 | Korlym |
| Ardelyx, INC. | $46.85 | 2024 | Ibsrela |
| Cardinal Health 200 LLC | $45.00 | 2021 | |
| Akebia Therapeutics INC | $38.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $38.53 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $38.09 | 2019-2023 | Korsuva, Velphoro |
| Becton, Dickinson and Company | $32.69 | 2025 | Covera |
| Scpharmaceuticals INC. | $26.40 | 2025 | |
| Lilly USA, LLC | $25.27 | 2025 | Jardiance |
| Renalytix Ai, INC. | $24.23 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Vantive US Healthcare LLC | $23.69 | 2025 | Renal - Pd |
| Alnylam Pharmaceuticals INC. | $23.67 | 2021 | |
| Hikma Pharmaceuticals USA | $23.57 | 2019 | |
| Ani Pharmaceuticals, INC. | $21.97 | 2025 | Purified Cortrophin Gel |
| Argon Medical Devices, INC. | $18.67 | 2024 | Clot Management |
| Abbvie INC. | $18.08 | 2023 | |
| Apellis Pharmaceuticals, INC. | $15.58 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Maya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.